Opioid REMS Advisory Committee May Tackle Mandatory Education
This article was originally published in The Pink Sheet Daily
FDA notes its FDAAA mandate in scheduling the two-day review, but will meeting focus on reducing burden to health care system or increasing requirements?
You may also be interested in...
Only about one-third of biosimilars received a first-cycle approval from US FDA after product quality discussions during the mid-assessment-cycle meeting, according to an interim report on the biosimilar application review program.
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.